How can engineered exosomes deliver Gouteng compound into AD brains?

Question

Accepted Answer

Engineered Exosomes Enhance Gouteng Compound Delivery to Alzheimer's Disease Brains

Researchers have developed a novel method to deliver the Gouteng compound Corynoxine-B to the brains of mice with Alzheimer's disease (AD) by engineering exosomes. These modified exosomes, derived from manipulated neuronal cells, exhibit an enhanced capacity to target and penetrate the blood-brain barrier, thereby delivering the therapeutic compound to affected brain regions. This engineered system facilitates the compound's interaction with neuronal cells and leads to a reduction in amyloid-beta protein accumulation.
Exosome Engineering for Targeted Delivery

To improve the delivery of Corynoxine-B, scientists engineered exosomes by manipulating neuronal cells in mice to overexpress the adaptor protein Fe65 on their surface. Fe65 plays a role in the processing of amyloid-beta precursor protein (APP), a key factor in AD development. The presence of Fe65 on the exosome surface significantly enhanced their ability to specifically target and interact with neuronal cells that exhibit elevated APP levels, a hallmark of AD.
Crossing the Blood-Brain Barrier

The engineered exosomes, once loaded with Corynoxine-B, demonstrated the capability to traverse the blood-brain barrier. This crucial step allows the therapeutic compound to reach the brain, overcoming a significant obstacle in AD treatment. This ability is attributed to the specific targeting mechanism facilitated by the engineered Fe65 protein on the exosome surface.
Reduction of Amyloid-Beta Protein and Cognitive Improvement

Upon successful delivery to the brain, the engineered exosomes loaded with Corynoxine-B were found to induce autophagy, a cellular process vital for neuronal health. This intervention resulted in a 30% reduction in accumulated amyloid-beta protein in the mice models. Furthermore, behavioural tests indicated a 25% recovery in cognitive and locomotor functions, suggesting the therapeutic potential of this delivery system.

Reading history

Hide →

This history is cleared when the page is closed.

How can engineered exosomes deliver Gouteng compound into AD brains?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends